Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment of BBB shuttle–siRNA ...

REDMOND, WA, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- The End Brain Cancer Initiative Partners with Belay ...

According to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology, preclinical studies using <ALPHA>DAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both ...

SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the ...

Dr. Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric ...

Recent advancements highlight the intricate interplay between the heart and brain, underscoring their profound influence on each other, especially concerning central nervous system (CNS) neurological ...

As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) ...

- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...

In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / ...